Invivyd, Inc., a biotechnology company headquartered in Waltham, United States, operates within the Health Care sector and is publicly traded on the Nasdaq. The company specializes in the development of next-generation candidate antibodies aimed at the prevention and treatment of COVID-19. Invivyd is currently focusing on advancing two specific molecules, known as NVD200, through near-term clinical development for combined use. These efforts are part of the company’s broader strategy to address the ongoing challenges posed by the COVID-19 pandemic.
As of August 11, 2026, Invivyd’s stock closed at $0.732. The company’s market capitalization stands at approximately $218.01 million. Over the past year, the stock has experienced significant volatility, with a 52-week high of $3.07 recorded on November 16, 2025, and a 52-week low of $0.483 on August 20, 2025. This fluctuation reflects the dynamic nature of the biotechnology sector and the market’s response to the company’s developmental milestones and broader industry trends.
Invivyd’s financial metrics indicate a Price Earnings (P/E) ratio of -3.13, which is not uncommon in the biotechnology industry, particularly for companies in the development phase without positive earnings. This negative P/E ratio underscores the speculative nature of investing in companies like Invivyd, which are heavily reliant on the successful progression of their clinical trials and regulatory approvals.
The company’s global reach is facilitated through its online presence, with its official website accessible at www.invivyd.com . This platform serves as a critical resource for stakeholders seeking information on Invivyd’s research initiatives, clinical trial updates, and strategic partnerships.
Invivyd’s commitment to advancing its NVD200 molecules highlights its dedication to innovation in the fight against COVID-19. The company’s progress in clinical development is closely monitored by investors and industry analysts, as successful outcomes could significantly impact its market valuation and position within the biotechnology sector.
In summary, Invivyd, Inc. remains focused on its mission to develop effective therapeutic solutions for COVID-19, with its efforts centered around the NVD200 molecules. The company’s performance on the Nasdaq and its financial metrics reflect the inherent risks and potential rewards associated with biotechnology investments. As Invivyd continues to navigate the complexities of drug development, its success will likely hinge on the outcomes of its clinical trials and the broader market’s reception to its innovations.
